Learning Center

Support that helps you succeed with Varithena®

What are your peers saying about treating GSV system incompetence with Varithena®? Click below to find out. Varithena® is indicated for the treatment of C2-C6 patients and improves the symptoms of the superficial venous incompetence above and below the knee.


If you would like materials to help tell your patients about Varithena® including patient brochures, posters, press release templates and web announcements, please Contact Us or discuss with your Varithena® Sales representative.

Case Studies

Successful ablation of the Great Saphenous Vein (GSV) with Varithena® following two failed attempts with laser ablation

Dr. Cindy B. Asbjornsen of the Vein Healthcare Center in South Portland, ME shares a successful Varithena® treatment story after two failed attempts of laser ablation treatments in a 58 year old male presenting with C3 disease.

Successful ablation of large diameter GSV with Varithena®

Dr. Navetta shares the story of a 57 year old female suffering for over 20 years with CEAP C3 disease in the left leg. A small dose of Varithena® resulted in closure immediately after treatment with complete resolution of symptoms.

Varithena® can succesfully improve both symptoms and appearances of pedal varicosities

An 82 year old female with bilateral venous insufficiency is treated successfully with Varithena® after a previous unsuccessful laser ablation treatment 6 months prior. Dr. Hassan Kafri reports clinical and visual improvement and Varithena® as an excellent option for difficult areas.

Successful re-treatment with Varithena® following endovenous laser ablation and PCF treatments

Dr. Bruce Hoyle shares this patient's Varithena® story. A 36 year old female with history of symptomatic bilateral CEAP C2 disease was re-treated with Varithena® after unsuccessful laser ablation and physician compounded foam treatments. The patient was happy to report visible improvement at 4 weeks and no pain at 8 weeks.

Varithena® is a minimally invasive procedure and ideal for challenging tortuous varicose veins

Dr. KathyLee Santangelo shares a patient story of a C4 patient who was treated in one session with Varithena® and went from a VCSS of 10 to VCSS of 1 at 6 month post-treatment.

Webinar Recordings

Webinar: Treating GSV-System Incompetence with Varithena®

How do you treat your C2-C6 patients? Dr. Michael Shao presents procedure tips and personal cases on treating GSV-System incompetence with Varithena®.


Supplemental Learning

Varithena® Supplemental Learning Course

Learn more about Varithena® and its use in varicose vein therapy with this four part online course


Contact your
Territory Sales Manager

Contact Customer Service at

1-855-971-VEIN (8346)

Monday through Friday,
8 am to 5 pm ET

Contact Us

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.


Varithena®  (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena®  improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.


The use of Varithena®  is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease.

Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately.

Varithena®  can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis.

Physicians administering Varithena®  must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena® .

See Full Prescribing Information for Varithena®.

Follow Us